Daymark Wealth Partners LLC Boosts Position in Johnson & Johnson (NYSE:JNJ)

Daymark Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 304,204 shares of the company's stock after purchasing an additional 6,033 shares during the quarter. Johnson & Johnson makes up 1.6% of Daymark Wealth Partners LLC's holdings, making the stock its 15th largest position. Daymark Wealth Partners LLC's holdings in Johnson & Johnson were worth $44,462,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Innealta Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth approximately $27,000. MFA Wealth Advisors LLC purchased a new position in Johnson & Johnson in the 2nd quarter valued at $43,000. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $44,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Johnson & Johnson during the second quarter worth $46,000. Finally, Grayhawk Investment Strategies Inc. raised its position in shares of Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company's stock valued at $48,000 after buying an additional 259 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Daiwa America lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 23rd. Daiwa Capital Markets cut Johnson & Johnson from an "outperform" rating to a "neutral" rating and cut their price target for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Morgan Stanley boosted their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 18th. TD Securities reduced their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, The Goldman Sachs Group cut their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a "neutral" rating for the company in a research report on Friday, July 19th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $173.21.

Johnson & Johnson Trading Up 0.5 %

Shares of JNJ traded up $0.75 during midday trading on Thursday, hitting $161.35. 6,121,979 shares of the stock were exchanged, compared to its average volume of 7,144,508. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The firm has a market cap of $388.32 billion, a P/E ratio of 10.03, a P/E/G ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The stock has a fifty day simple moving average of $161.90 and a 200 day simple moving average of $154.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter last year, the firm posted $2.80 earnings per share. The business's revenue for the quarter was up 4.3% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson's dividend payout ratio (DPR) is presently 30.92%.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.